Expert Interviews

A focused discussion on how ADT is used as the backbone of prostate cancer therapy across different prostate cancer risk groups and according to metastatic and castration sensitivity status.

Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD draw conclusions from two post hoc analyses of the REACH2 trial and share clinical pearls for community clinicians treating patients with acute Graft-Versus-Host Disease.

Expert panelists share their perspective on novel and combination strategies being investigated in the setting of metastatic renal cell carcinoma.

Switching focus to a second clinical scenario, key opinion leaders on metastatic renal cell carcinoma discuss the treatment landscape for favorable-risk disease.

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

Nora Biran, MD, and David Siegel, MD, offer closing remarks on the MM treatment landscape.

A patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.

Experts on graft-vs-host disease offer clinical insights for clinicians treating patients with GVHD.

David O’Malley, MD, an expert gynecologic oncologist, details molecular profiling and risk stratification for patients with advanced endometrial carcinoma.

David O’Malley, MD, provides a comprehensive overview of endometrial carcinoma and treatment options for patients in this setting.

The addition of radiation to chemotherapy did not improve overall survival in patients with advanced endometrial cancer, according to an expert from Northwestern Medicine.

Panelists engage with a post hoc analysis of the REACH2 trial comparing early versus late treatment with ruxolitinib in patients with steroid-refractory acute Graft-Versus-Host Disease.

Two subject matter experts discuss a post hoc analysis of the REACH2 trial, focusing on the impact of cytopenias on treatment outcomes in patients with steroid-refractory acute Graft-Versus-Host Disease.

Before closing out their review of the first clinical scenario, panelists consider the general state of prognoses within metastatic renal cell carcinoma.

A brief review of dose hold or adjustment strategies in the setting of metastatic renal cell carcinoma and when it is appropriate to consider these options.

Practical advice on the management of renal cell carcinoma provided for healthcare professionals, patients, and caregivers alike.

The panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.

Dr Sandy Wong reviews data from a patient subgroup analysis of the MAIA trial in transplant-ineligible NDMM.

Myeloma experts share their thoughts on the future of multiple myeloma treatment.